{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:17:53Z","timestamp":1772162273735,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1124\/dmd.118.085951","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T15:35:16Z","timestamp":1553528116000},"page":"665-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise"],"prefix":"10.1016","volume":"47","author":[{"given":"Dennis A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.085951_bib1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0090-9556(25)07633-0","article-title":"Central nervous system kinetics of atenolol and metoprolol in the dog during long term treatment","volume":"17","author":"Abrahamsson","year":"1989","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.085951_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","article-title":"Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study","volume":"5","author":"Ahn","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1124\/dmd.118.085951_bib3","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1124\/dmd.118.085951_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00315572","article-title":"Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity","volume":"38","author":"Bannwarth","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.118.085951_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.085951_bib6","doi-asserted-by":"crossref","first-page":"41707","DOI":"10.1038\/srep41707","article-title":"Microfluidic cell isolation technology for drug testing of single tumor cells and their clusters","volume":"7","author":"Bithi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.118.085951_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12987-017-0078-x","article-title":"Revisiting atenolol as a low passive permeability marker","volume":"14","author":"Chen","year":"2017","journal-title":"Fluids Barriers CNS"},{"key":"10.1124\/dmd.118.085951_bib8","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/clpt.2013.78","article-title":"Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver","volume":"94","author":"Chu","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.085951_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1124\/dmd.118.085951_bib10","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.1073\/pnas.94.20.10594","article-title":"Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein","volume":"94","author":"Dey","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.118.085951_bib11","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/JTO.0000000000000455","article-title":"Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib","volume":"10","author":"Gainor","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1124\/dmd.118.085951_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1749-6632.1971.tb46890.x","article-title":"Factors affecting drug metabolism","volume":"179","author":"Gillette","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/dmd.118.085951_bib13","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/annonc\/mdu041","article-title":"Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases","volume":"25","author":"Gori","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1124\/dmd.118.085951_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00003495-199039060-00006","article-title":"Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses","volume":"39","author":"Grant","year":"1990","journal-title":"Drugs"},{"key":"10.1124\/dmd.118.085951_bib15","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.1021\/acs.analchem.7b00367","article-title":"Single-cell mass spectrometry of metabolites extracted from live cells by fluidic force microscopy","volume":"89","author":"Guillaume-Gentil","year":"2017","journal-title":"Anal Chem"},{"key":"10.1124\/dmd.118.085951_bib16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/cpt.1183","article-title":"Advancing predictions of tissue and intracellular drug concentrations using in vitro, imaging and physiologically based pharmacokinetic modeling approaches","volume":"104","author":"Guo","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.085951_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1742-7843.2009.00517.x","article-title":"Active-site concentrations of chemicals\u2014are they a better predictor of effect than plasma\/organ\/tissue concentrations?","volume":"106","author":"Hammarlund-Udenaes","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/dmd.118.085951_bib18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2165\/00003088-198510060-00006","article-title":"Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs","volume":"10","author":"Holdiness","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.118.085951_bib19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/sj.bjp.0704620","article-title":"Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins","volume":"135","author":"Hooiveld","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.118.085951_bib20","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1056\/NEJMra1413919","article-title":"Treatment of tuberculosis","volume":"373","author":"Horsburgh","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.085951_bib21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2133\/dmpk.DMPK-11-RG-043","article-title":"Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics\/pharmacodynamics and toxicokinetics\/toxicodynamics","volume":"26","author":"Hoshino-Yoshino","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.118.085951_bib22","first-page":"147ra111","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2","volume":"15","author":"Iliff","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1124\/dmd.118.085951_bib23","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/dmd.106.012294","article-title":"Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios","volume":"35","author":"Kalvass","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.085951_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.107.119560","article-title":"Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data","volume":"323","author":"Kalvass","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.085951_bib25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1124\/dmd.106.011445","article-title":"Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception","volume":"35","author":"Kalvass","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.085951_bib26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jps.20792","article-title":"Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications","volume":"96","author":"Kaufmann","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.085951_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/gtc.12022","article-title":"Activity-based kinase profiling of approved tyrosine kinase inhibitors","volume":"18","author":"Kitagawa","year":"2013","journal-title":"Genes Cells"},{"key":"10.1124\/dmd.118.085951_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0022-2828(08)80024-7","article-title":"Inhibition of cardiac L-type calcium channels by quaternary amlodipine: implications for pharmacokinetics and access to dihydropyridine binding site","volume":"27","author":"Kwan","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"10.1124\/dmd.118.085951_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-015-0028-8","article-title":"Breast cancer brain metastases: the last frontier","volume":"4","author":"Leone","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"10.1124\/dmd.118.085951_bib30","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1124\/dmd.108.024125","article-title":"Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid","volume":"37","author":"Liu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.085951_bib31","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/mp4000822","article-title":"Rapid measurement of intracellular unbound drug concentrations","volume":"10","author":"Mateus","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.118.085951_bib32","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/156802611795371288","article-title":"Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance","volume":"11","author":"Mercer","year":"2011","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.118.085951_bib33","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/JTO.0000000000000468","article-title":"CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment","volume":"10","author":"Metro","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1124\/dmd.118.085951_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","article-title":"Why are tumour blood vessels abnormal and why is it important to know?","volume":"100","author":"Nagy","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.118.085951_bib35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/clpt.1987.196","article-title":"Total and free ketoprofen in serum and synovial fluid after intramuscular injection","volume":"42","author":"Netter","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.118.085951_bib36","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"10.1124\/dmd.118.085951_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jnnp.53.1.81","article-title":"The blood\/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis","volume":"53","author":"Phuapradit","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1124\/dmd.118.085951_bib38","doi-asserted-by":"crossref","first-page":"e000262","DOI":"10.1136\/esmoopen-2017-000262","article-title":"Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion","volume":"3","author":"Preusser","year":"2018","journal-title":"ESMO Open"},{"key":"10.1124\/dmd.118.085951_bib39","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/jm501535r","article-title":"CNS drug design: balancing physicochemical properties for optimal brain exposure","volume":"58","author":"Rankovic","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.118.085951_bib40","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.085951_bib41","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/jps.20323","article-title":"Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst \u03b2-blocking drugs in rat","volume":"94","author":"Rodgers","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.085951_bib42","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions [published correction appears in J Pharm Sci 2007;96:3153\u20133154]","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.118.085951_bib43","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.085951_bib44","doi-asserted-by":"crossref","first-page":"e02266","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme drug tolerance of Mycobacterium tuberculosis in caseum","volume":"62","author":"Sarathy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1124\/dmd.118.085951_bib45","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0006-2952(99)00229-4","article-title":"Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements","volume":"58","author":"Schmid","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.118.085951_bib46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.118.085951_bib47","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2125.2001.01471.x","article-title":"Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine","volume":"52","author":"Tagawa","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.118.085951_bib48","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1007\/s11095-011-0601-8","article-title":"Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer","volume":"29","author":"Taskar","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.085951_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17460441.2.1.51","article-title":"The importance of plasma protein binding in drug discovery","volume":"2","author":"Trainor","year":"2007","journal-title":"Expert Opin Drug Discov"},{"key":"10.1124\/dmd.118.085951_bib50","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"10.1124\/dmd.118.085951_bib51","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0924-8579(01)00406-X","article-title":"Macrolides: pharmacokinetics and pharmacodynamics","volume":"18","author":"Van Bambeke","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1124\/dmd.118.085951_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1124\/dmd.118.085951_bib54","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF02354268","article-title":"Prediction of sleep disorders induced by \u03b2-adrenergic receptor blocking agents based on receptor occupancy","volume":"23","author":"Yamada","year":"1995","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.118.085951_bib55","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejps.2017.11.011","article-title":"Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach","volume":"112","author":"Yamamoto","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.118.085951_bib56","doi-asserted-by":"crossref","first-page":"368ra172","DOI":"10.1126\/scitranslmed.aag0976","article-title":"AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases","volume":"8","author":"Yang","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1124\/dmd.118.085951_bib57","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J Med Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.085951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:50:32Z","timestamp":1740037832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0090955624079789"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.085951","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735400114.793566619","asserted-by":"object"}]},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.085951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}